Samsung Biologics Strike Vote Highlights Governance Risks for CDMO Clients
Event summary
- 95.52% of Samsung Biologics Labor Union members voted to strike, with 95.38% turnout between March 24-29, 2026.
- Union cites unresolved governance failures, ESG management concerns, and rigid labor policies as core issues.
- Management's wage offer below 2025 levels despite 56.6% YoY operating profit increase.
- Phased strike actions planned starting April 22, potentially escalating to general strike on May 1.
- Union warns of structural supply chain risks for global CDMO clients.
The big picture
The strike vote at Samsung Biologics highlights growing tensions between labor unions and management in South Korea's biopharmaceutical sector. As one of the world's largest CDMO providers, any disruption to operations could have ripple effects across global biotech supply chains. The dispute also underscores the challenges of maintaining independent governance structures within large conglomerate groups. With $3.2 billion in revenue (2025), Samsung Biologics serves major pharmaceutical companies, making this labor conflict particularly sensitive for its international client base.
What we're watching
- Supply Chain Disruption
- How prolonged labor action will impact Samsung Biologics' ability to fulfill CDMO contracts for international clients.
- Governance Dynamics
- Whether management can address union concerns without compromising Samsung Electronics' group-level wage guidelines.
- Regulatory Scrutiny
- The pace at which South Korean authorities may intervene given the union's allegations of unfair labor practices.